Tags

Type your tag names separated by a space and hit enter

Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies.
Int Rev Psychiatry. 2009 Apr; 21(2):122-33.IR

Abstract

Medicinal chemistry has produced small-molecule agents with drug-like character that potently and safely modulate the activity of discrete endocannabinoid system components as potential treatments for medical disorders, including various psychiatric conditions. Two cannabinoid (CB) receptors (CB1 and CB2) currently represent prime endocannabinoid-system therapeutic targets for ligands that either mimic endocannabinoid signalling processes and/or potentiate endocannabinoid-system activity (agonists) or attenuate pathologically heightened endocannabinoid-system transmission (antagonists). Two endocannabinoid deactivating enzymes, fatty acid amide hydrolase (FAAH) and soluble monoacylglycerol lipase (MGL), are increasingly prominent targets for inhibitors that indirectly potentiate endocannabinoid-system signalling. Continued profiling of drug candidates in relevant disease models, identification of additional cannabinoid-related therapeutic targets, and validation of new pharmacological modes of endocannabinoid system modulation will undoubtedly invite further translational efforts in the cannabinoid field for treating psychiatric disorders and other medical conditions.

Authors+Show Affiliations

Center for Drug Discovery, Northeastern University, Boston, Massachusetts 02115-5000, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19367506

Citation

Janero, David R., et al. "Pharmacotherapeutic Modulation of the Endocannabinoid Signalling System in Psychiatric Disorders: Drug-discovery Strategies." International Review of Psychiatry (Abingdon, England), vol. 21, no. 2, 2009, pp. 122-33.
Janero DR, Vadivel SK, Makriyannis A. Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies. Int Rev Psychiatry. 2009;21(2):122-33.
Janero, D. R., Vadivel, S. K., & Makriyannis, A. (2009). Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies. International Review of Psychiatry (Abingdon, England), 21(2), 122-33. https://doi.org/10.1080/09540260902782778
Janero DR, Vadivel SK, Makriyannis A. Pharmacotherapeutic Modulation of the Endocannabinoid Signalling System in Psychiatric Disorders: Drug-discovery Strategies. Int Rev Psychiatry. 2009;21(2):122-33. PubMed PMID: 19367506.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies. AU - Janero,David R, AU - Vadivel,Subramanian K, AU - Makriyannis,Alexandros, PY - 2009/4/16/entrez PY - 2009/4/16/pubmed PY - 2009/8/6/medline SP - 122 EP - 33 JF - International review of psychiatry (Abingdon, England) JO - Int Rev Psychiatry VL - 21 IS - 2 N2 - Medicinal chemistry has produced small-molecule agents with drug-like character that potently and safely modulate the activity of discrete endocannabinoid system components as potential treatments for medical disorders, including various psychiatric conditions. Two cannabinoid (CB) receptors (CB1 and CB2) currently represent prime endocannabinoid-system therapeutic targets for ligands that either mimic endocannabinoid signalling processes and/or potentiate endocannabinoid-system activity (agonists) or attenuate pathologically heightened endocannabinoid-system transmission (antagonists). Two endocannabinoid deactivating enzymes, fatty acid amide hydrolase (FAAH) and soluble monoacylglycerol lipase (MGL), are increasingly prominent targets for inhibitors that indirectly potentiate endocannabinoid-system signalling. Continued profiling of drug candidates in relevant disease models, identification of additional cannabinoid-related therapeutic targets, and validation of new pharmacological modes of endocannabinoid system modulation will undoubtedly invite further translational efforts in the cannabinoid field for treating psychiatric disorders and other medical conditions. SN - 1369-1627 UR - https://www.unboundmedicine.com/medline/citation/19367506/Pharmacotherapeutic_modulation_of_the_endocannabinoid_signalling_system_in_psychiatric_disorders:_drug_discovery_strategies_ L2 - http://www.tandfonline.com/doi/full/10.1080/09540260902782778 DB - PRIME DP - Unbound Medicine ER -